Monopar Therapeutics Inc Stock
Monopar Therapeutics Inc Stock price
Key metrics
| Market capitalization | $225.65m |
| Enterprise Value | $171.10m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 4.21 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-17.66m |
| Free Cash Flow (TTM) Free Cash Flow | $-10.41m |
| Cash position | $54.55m |
Is Monopar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Monopar Therapeutics Inc Stock Analysis
Analyst Opinions
4 Analysts have issued a Monopar Therapeutics Inc forecast:
Analyst Opinions
4 Analysts have issued a Monopar Therapeutics Inc forecast:
Financial data from Monopar Therapeutics Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -18 -18 |
120%
120%
|
EBIT (Operating Income) EBIT | -18 -18 |
120%
120%
|
| Net Profit | -17 -17 |
118%
118%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Monopar Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monopar Therapeutics Inc Stock News
Company Profile
Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
| Head office | United States |
| CEO | Chandler Robinson |
| Employees | 16 |
| Founded | 2014 |
| Website | www.monopartx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
